<DOC>
	<DOC>NCT01068704</DOC>
	<brief_summary>The purpose of this study is to determine if BMS-690514 + letrozole will be more effective than lapatinib + letrozole in patients who have metastatic hormone receptor positive breast cancer after developing progressive disease immediately following adjuvant antiendocrine therapy</brief_summary>
	<brief_title>Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Documented invasive breast cancer Greater than 10% tumor cells positive for estrogen receptor and/or progesterone receptor HER2+ and HER2 (Human Epidermal growth factor Receptor) disease Rapid disease progression despite treatment with tamoxifen, anastrozole or exemestane ECOG Performance status = 0 or 1 Prior hormonal therapy for metastatic disease Prior hormonal therapy with letrozole for adjuvant disease Symptomatic brain metastases Prior treatment with any tyrosine kinase inhibitor</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>